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DAOUD, E.G., ET AL.: Rise in Chronic Defibrillation Energy Requirements Necessitating Implantable De-
fibrillator Lead System Revision. The chronic defibrillation energy requirement (DER) is believed to re-
main clinically stable in patients with defibrillators. Six patients (two with an epicardial and four with a
nonthoracotomy system) were identified with a rise in their chronic DER, which eliminated a 10-J safety
margin, thus necessitating a defibrillator lead system revision. The mean increase in DER was 14.7 ± 4 J
and was discovered at a mean of 16.0 ± 18 months (range 2-41) following implantation. Management in-
cluded placement of a defibrillator with a biphasic waveform, placement of an additional defibrillation
electrode, or both. At 2 months following revision of the defibrillation system, a 10-f DER safety margin
was present in each patient. In some patients, there is a progressive increase in the chronic DER with elim-
ination of a 10-f safety margin necessitating revision of the defibrillation system. Routine reevaluation of
the chronic DER, therefore, is necessary to identify these patients. (PACE 1997; 20[Pt. I]:714-719)
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Introduction
Either an epicardial or a nonthoracotomy sys-
tem (NTL) can be used in combination with ah im-
plantable cardioverter defibrillator (ICD). The
chronic defibrillation energy requirement (DER)
with an epicardial lead system is thought to re-
main stable.^ However, with an NTL system, the
DER may rise significantly during the first 2
months after implantation, although an adequate
defibrillation safety margin has persisted.^ The
purpose of this report is to describe six patients,
four with an NTL system and two with an epicar-
dial lead system, who had a rise in their DER 2-41
months after ICD implantation resulting in loss of
an adequate defibrillation safety margin and re-
quiring revision of the lead system.
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Methods
Between November 1992 and January 1994, 6
of 162 patients (4%) were prospectively identified
to have a rise in the chronic DER that eliminated a
10-J defibrillation safety margin. In these patients,
revision of the defibrillating lead system was per-
formed.
Clinical Characteristics
The mean patient age was 64 ± 10 years (range
52-78); five patients were men. Five patients had
an ischemic cardiomyopathy, and one patient had
a nonischemic cardiomyopathy. The mean left ven-
tricular ejection fraction was 0.22. Four patients
presented with cardiac arrest, one with syncope
and one with sustained monomorphic ventricular
tachycardia (VT). Five patients had inducible
monomorphic VT at baseline programmed ventric-
ular stimulation. The tachycardias were not sup-
pressed with amiodarone therapy in two patients or
sotalol therapy in two patients. Four patients had
transvenous lead systems and two patients had epi-
cardial lead systems. All patients had defibrillators
that delivered monophasic shocks.
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Determination of Acute DER
The DER was determined either with succes-
sive successful shocks or with a step-down
protocol until failure. For the two patients
with epicardial lead systems, successive shocks,
three shocks at 25 J or two shocks at 20 J, were re-
quired. For the patients with NTL systems, the
DER was determined hy the step-down testing
protocol. The acute DER was defined to be the
lowest energy that successfully defihrillated ven-
tricular fibrilfation (VF) to sinus rhythm. Rou-
tinely, testing began at 25 J, then 20, 15, 10, 5,
and finally 1 J. If 25 J failed, the electrode polarity
was reversed and the step-down protocol was
retested, beginning at 25 J. If 25 J failed with re-
verse polarity, the DER was defined as > 25 J and
a sub- cutaneous patch was added. An adequate
de- fibrillation safety margin was defined as a
DER at least 10 J less than the maximum ICD out-
put.
Initial ICD System and Acute DER Results
(Table I)
In each patient, the initially implanted ICD
generator delivered shocks with a monophasic
waveform. For the two patients with an epicardial
lead system, defihrillation in one patient was be-
tween a left ventricle epicardial patch and a
transvenous spring coil lead positioned in the su-
perior vena cava. In the second patient, defibrilla-
tion was between two large epicardial patches.
For the four patients with NTL systems, one
patient required a transvenous lead alone, one pa-
tient required a transvenous lead with a subcuta-
neous patch electrode, and two patients required
two transvenous electrodes and a subcutaneous
patch electrode. Each lead was placed through a
left subclavian vein and one lead was positioned
in the right ventricular apex. In the patients with
two transvenous leads, the second lead was posi-
tioned at the superior vena cava-left brachy-
cephalic vein junction in one patient, and ih the
coronary sinus in the other patient. The suhcuta-
neous patch electrodes were placed through an in-
cision in the anterior axillary line extending over
the apex of the left ventricle. The patch was
placed posteriorly extending beyond the posterior
axillary line.
Postimplant Care
All patients had predischarge testing of the
ICD. Testing included induction of VF and defibril-
lation at the maximum programmable output of the
ICD generator. In patients with an NTL system, ini-
tial outpatient follow-up was in the electrophysiol-
ogy laboratory 2 months following implantation.
VF was induced and proper ICD sensing and defib-
rillation were tested at the programmed output of
the generator. Testing was complete if the initial
ICD shock successful defibrillated VF to sinus
rhythm. Subsequent follow-up was at 2- to 3-month
intervals in the outpatient ICD clinic.
ICD Replacement for Battery End-of-Life
When the hattery charge was low, the genera-
tor was electively replaced in the electrophysiology
laboratory with the patient under sedation with in-
travenous midazolam and fentanyl. The ICD pocket
was opened and the leads were removed from the
generator. Capture threshold, sensitivity, and
impedance were measured for the ventricular sens-
ing leads. Ventricular fihrillation was then induced
with alternating current through the ventricular
sensing leads. Defibrillation testing, as descrihed
above, was completed to confirm a 10-J DER safety
margin.
Evaluation of the Lead System
Once the chronic DER was documented to
have risen and eliminated a 10-J safety margin,
noninvasive techniques were used to investigate
potential etiologies for the rise in DER. The position
and integrity of the lead system was evaluated with
chest roentgenograms. Ventricular capture thresh-
old and sensitivity were determined for the sensing
lead. The shocking lead impedance was also noted
for the defibrillating electrodes, either noninva-
sively, if available, or at the time of revision of the
defibrillation system. If these values were appro-
priate, a surface echocardiogram was performed to
assess a change in left ventricular anatomy or func-
tion.
Statistical Analysis
Continuous variables are expressed as mean ±
1 SD. Differences between continuous variables
were tested hy Student's f-test. P < 0.05 was con-
sidered significant.
PACE, Vol. 20 March 1997, Part I 715
DAOUD, ET AL.
Table I.
Summary of Patient Management





Acute Chronic DER Mode of Identifying Rise Chronic










1 Epicardial patch with an
SVC electrode +
monophasic ICD
2 Epicardial patches +
monophasic ICD
2 NTLs with an SQ patch +
monophasic IGD
NTL with an SQ patch +
monophasic IGD
NTL + monophasic IGD
















Evaluation of 1 year DER
Routine reevaluation ot IGD
Routine reevaluation of IGD
Evaluation for pacemaker-
IGD interaction
> 3 0 J
30 J
> 3 4 J
> 3 4 J





















DER = defibrillation energy requirement; ICD = implantable cardioverter defibrillator; NTL = nonthoracotomy lead; SQ = subcutaneous; SVC = superior vena
cava.
Results
The acute DER was determined with succes-
sive successful shocks for the two patients with
epicardial lead systems. The DER was < 15 J in the
patient with the single left ventricular patch and
< 20 J for the patient receiving two large patches.
The acute DER for the transvenous lead systems
was determined by the step-down protocol and
was 15 J with a lead-alone configuration, 25 J with
a lead and a subcutaneous patch, and 18 J in the
two patients requiring two leads and a subcuta-
neous patch electrode. Predischarge testing of the
ICD system demonstrated proper sensing and de-
fibrillation of VF with a single ICD shock for all
patients.
Rise in DER at 2 Months (Table I)
Three patients were identified to have a rise
in their DER beyond a 10-J safety margin at 2
months following ICD implantation. No patients
had required ICD therapies since implantation; in
one patient, beta-blockade therapy was initiated.
In each patient, 34 J failed to defibrillate VF. The
integrity of each NTL was evaluated noninva-
sively and was intact. Management of the rise in
DER was focused on altering the defibrillation
configuration. In one patient, the subcutaneous
patch electrode was removed and a single large
epicardial patch was implanted. The acute DER
was 10 J. In a second patient, the addition of a sub-
cutaneous defibrillating patch, reversing the
shocking polarity, and testing multiple defibrilla-
tion configurations all failed to lower the DER and
two epicardial patches were placed. The acute
DER was 20 J. In the final patient, 2 months after
initial ICD implantation, a pacemaker was im-
planted. When evaluating for pacemaker-ICD in-
teraction, VF failed to convert to sinus rhythm
with a 34-J shock. Since multiple defibrillating
configurations and polarities were assessed dur-
ing the initial ICD implantation, the implanting
shocking configuration was assumed to be opti-
mal, and the ICD was replaced with one that de-
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livered a biphasic waveform with a maximum out-
put of 37 J. The acute DER was 27 J.
Rise in DER Beyond 2 Months (Table I)
In the two patients with epicardial lead sys-
tems, the rise in DER was identified at the time of
elective replacement of the ICD generator, 38 ± 4
months after initial epicardial ICD system implan-
tation. Each patient had appropriate ICD shock
therapy with their original ICD system. One pa-
tient had one episode of syncope associated with
three sequential shocks. In both patients, the in-
tegrity of the leads was intact and a transthoracic
echocardiogram revealed no significant changes
in left ventricular structure and function com-
pared to the time of initial ICD implantation. In
one patient, the chronic DER rose to > 30 J. De-
spite reversing the defibrillation polarity,^'* the
DER was unchanged and an ICD with a biphasic
waveform was implanted. The DER was then 15 J.
For the second patient with an epicardial lead
system, the chronic DER rose to 34 J. A superior
vena cava electrode was placed through the left
subclavian vein, and the DER was 25 J. At predis-
charge testing, VF was cardioverted to sinus
rhythm by a 34-J shock. Three months later, dur-
ing evaluation for pacemaker-ICD interaction, the
DER was found to be 30 J. Reversing ICD electrode
polarity or altering the electrode configuration
were unsuccessful in achieving a 10-J DER safety
margin. An ICD with a biphasic waveform was im-
planted and the step-down DER was 10 J. In the re-
maining patient, the rise in the chronic DER was
identified at 1-year evaluation of the DER. The pa-
tient had no ICD therapies since implantation and
his chronic DER rose from 18 J to > 34 J. The de-
fibrillation system included two transvenous
leads and a subcutaneous patch. We anticipated
opening the ICD pocket and testing reverse polar-
ity, and if this was unsuccessful in lowering the
DER, a biphasic waveform device was to be im-
planted. The patient, however, refused any further
procedures and left the hospital against medical
advice. The patient has been followed for 5
months and has not received any ICD therapies.
Defibrillation Impedance
The defibrillation impedance at the time of
initial ICD implantation was 45 ± 7.3 il. The
impedance at the time of lead revision was 49 ±
6.8 a (P = 0.33).
Two-Month Follow-Up
Repeat evaluation of the DER was completed
2 months after revision of the ICD system. The
DER was at least 10 J less than the maximum pro-
grammable output of the ICD in each patient.
Discussion
These six cases document that a progressive
increase in DER may occur more than 6 months af-
ter ICD implantation, both with NTL and epicar-
dial lead systems. The increased energy require-
ment may eliminate a 10-J defibrillation safety
margin present at the time of the initial implant
and necessitate a change in either the defibrilla-
tion configuration or the shock waveform.
In 5 of the 6 patients, a 10-J DER safety margin
was achieved by sequentially testing four meth-
ods: (1) reversal of the defibrillation polarity^*; (2)
placement of a defibrillating electrode or subcuta-
neous or epicardial patch; (3) placement of an ICD
that delivers a biphasic waveform^'^; or (4) a com-
bination of these three methods. This stepwise ap-
proach is based on achieving an adequate DER by
the least invasive and perhaps the most cost-effec-
tive revision of the ICD system. Placement of an
electrode or patch was successful in two patients,
changing to a biphasic waveform ICD was suc-
cessful in two patients, and placement of an elec-
trode and changing to a biphasic waveform ICD
was successful in one patient.
The clinical significance of a rise in the DER
and loss of a 10-J safety margin is unknown. In five
patients, the rise in the DER was detected during
routine ICD evaluation. One patient in this series
presented with syncope and required multiple
shocks. In this patient, the requirement for multi-
ple shocks implies that absence of a 10-J safety
margin may hold clinical significance. In the ab-
sence of shock therapy, as in the other five pa-
tients, the clinical significance of this finding is
uncertain.
Previous Reports
In other studies, a significant rise in DER was
noted to occur during the first 2 months after im-
plantation of an NTL system,^ but not after im-
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plantation of an epicardial lead system.^ The ob-
served DER elevation after NTL system implanta-
tion did not exceed adequate defibrillation energy
safety margins, and revision of the system was not
required in these studies. However, other investi-
gators have reported that a rise in the chronic DER
can occur and that ICD system revision may be
necessary.'^"^
Mechanisms of Increase in Chronic DER
The mean increase in chronic DER was > 14.7
± 4 J. The etiology of this increase is unclear.
There are four potential mechanisms. At any given
energy, successful defibrillation of VF is based on
a probability curve.^° It is possible that the rise in
DER determined at follow-up testing represents a
statistical phenomenon and repeated testing at the
same energy would reveal greater defibrillation
success. This theory seems unlikely, however,
since the follow-up DER was determined by the
step-down protocol. This method of DER determi-
nation correlates with approximately 70% of suc-
cess in animal models.^^
A loss of lead or patch integrity, position,
or contact with the myocardium is a second mech-
anism for a rise in chronic DER. Capture thresh-
old, impedance, sensitivity, and, if possible,
shocking impedance were determined. Progres-
sive scarring and fibrosis around the defibrillation
coils or patches could raise the shocking
impedance and, for epicardial patches, effusions
have been noted to develop between the patches
and the myocardium, which also raises the
impedance.^^ An increase in the shocking
impedance will decrease the delivered de-
fibrillation current and possibly raise the DER.
In this study, there was no significant change
in the impedance measured at implantation ver-
sus that at the time of revision. Additionally, fol-
low-up chest roentgenograms were compared to
predischarge films to evaluate for lead dislodg-
ment or fracture or crinkling of epicardial or sub-
cutaneous patches. Although an evaluation for
epicardial patch effusion was not completed for
our patients, the other investigated parameters did
not reveal a lead or patch complication.
Another possible mechanism for a rise in the
chronic DER is an interval change in the myocar-
dial substrate. An intercedent event, such as a my-
ocardial infarction, increase in heart size, or de-
crease in ejection fraction, may require greater
defibrillation energy. No patient had an interce-
dent myocardial infarction and repeat transtho-
racic echocardiograms were unchanged. This was
not noted in these patients.
Finally, alterations in autonomic tone or drug
therapy may affect DER.̂ '̂̂ ^ In one patient block-
ade therapy was initiated. A recent study suggests
that p-antagonists do not increase the DER^ ;̂ how-
ever, other antiarrhythmic agents have been
shown to increase the
Limitations
This study is limited by the small sample size.
However, there have been no previous reports
demonstrating the loss of an adequate defibrilla-
tion safety margin resulting in lead system
revision. An additional limitation is that each pa-
tient initially had a defibrillator with a monopha-
sic waveform; thus, these observations may
not apply to patients with a biphasic waveform
device.
Clinical Implications
These patients highlight the limited data that
exist about the chronic DER and, hence, the im-
portance of routine reevaluation of the chronic
DER 2 months after initial implantation of an ICD
with an NTL system, and at the time of ICD re-
placement for both epicardial and NTL systems.
Three of the six patients in this report were iden-
tified during a standard 2-month follow-up of the
chronic DER, and two patients were identified at
the time of ICD generator change approximately 3
years following the initial implant date. If the lead
system is demonstrated to be intact, management
of these patients should be directed at obtaining a
10-J DER safety margin by revising either the de-
fibrillation lead configvu-ation or the ICD defibril-
lation waveform.
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